Beam Therapeutics Inc. (BEAM) vs Zai Lab Limited Unsponsored ADR (ZLAB)

Beam Therapeutics Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Zai Lab Limited Unsponsored ADR is the larger, with a market value of $2.9B against $2.6B — 1.1× the size. Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against 5.10%. Zai Lab Limited Unsponsored ADR has the higher net margin (−41.9% vs −55.5%) and the higher return on invested capital (−129.3% vs −1,599.3%). Across the 18 metrics below, Beam Therapeutics Inc. leads on 10 and Zai Lab Limited Unsponsored ADR on 8.

Valuation

Metric BEAM ZLAB Biotechnology median
P/E n/m n/m 7.88
P/S 16.23 6.21 11.47
P/B 2.37 4.60 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 9.48 5.14 10.73
Earnings yield (3.38%) (6.85%) (28.84%)
Free cash flow yield (14.72%) (5.82%) (23.03%)

Profitability

Metric BEAM ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin (242.27%) (58.74%) 0.00%
Net margin (55.45%) (41.86%) 0.00%
Free cash flow margin (238.90%) (36.13%) 0.00%
Return on equity (8.18%) (26.91%) (57.72%)
Return on assets (6.23%) (16.81%) (49.22%)
Return on invested capital (1,599.30%) (129.34%) 0.00%

Growth

Metric BEAM ZLAB Biotechnology median
Revenue growth (TTM) 158.88% 5.10% 5.64%
EPS growth (last fiscal year) 82.31% 38.46% —
Revenue growth, 5-year CAGR 466.27% 56.54% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM ZLAB Biotechnology median
Debt to equity 0.09 0.39 0.00
Current ratio 14.57 2.13 4.73
Net debt to EBITDA 3.30 2.66 0.96

Dividend

Metric BEAM ZLAB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BEAM ZLAB Biotechnology median
Market cap 2.55b 2.85b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack